凯赛生物利润大增51%！长链二元酸产品放量，持续布局生物基复合材料

Core Viewpoint - The article highlights the strong performance of Kasei Bio in the third quarter of 2025, showcasing significant growth in revenue and profit, driven by the increasing sales of long-chain dicarboxylic acid products and the expansion into bio-based composite materials [2][4]. Financial Performance - Kasei Bio reported a total revenue of 2.545 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 14.90% [3]. - The net profit attributable to shareholders reached 451 million yuan, up 30.56% year-on-year [3]. - The company’s R&D investment totaled approximately 55.37 million yuan in the latest quarter, a decrease of 19.45% compared to the previous year [3]. Product and Market Development - Kasei Bio is a leading player in the long-chain dicarboxylic acid market, with its DC11-DC18 products dominating globally [4]. - The company has successfully replaced traditional chemical production methods with bio-manufacturing, enhancing product quality and reducing carbon emissions [4]. - Kasei Bio is expanding its market by developing bio-based polyamides and composites, which are expected to become a significant growth driver [4][5]. Green Composite Materials - Kasei Bio has initiated several projects in the bio-based composite materials sector, including the delivery of the world's first bio-based composite refrigerated container [5]. - The company’s bio-based composite materials are penetrating six major sectors, including new energy vehicles and clean energy, showcasing their versatility and environmental benefits [5]. - The shift towards green composite materials is driven by the need for sustainable solutions in response to carbon emission regulations [5]. Industry Trends and Events - The upcoming "2025 (Fourth) Green Composite Materials Forum" will focus on innovations in resin and fiber integration, aiming to address challenges in the industry and promote technological breakthroughs [6].